C
Chengzhi Zhou
Researcher at Guangzhou Medical University
Publications - 172
Citations - 2670
Chengzhi Zhou is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 22, co-authored 114 publications receiving 1416 citations. Previous affiliations of Chengzhi Zhou include Huazhong University of Science and Technology & Dongguan University of Technology.
Papers
More filters
Journal ArticleDOI
Characterization of Cytokine/Chemokine Profiles of Severe Acute Respiratory Syndrome
Yong Jiang,Jun Xu,Chengzhi Zhou,Zhenguo Wu,Shuqing Zhong,Jing-hua Liu,Wei Luo,Tao Chen,Qinghe Qin,Peng Deng +9 more
TL;DR: Induction of IP-10 is a critical event in the initiation of immune-mediated acute lung injury and lymphocyte apoptosis during the development of SARS, indicating a high risk of death.
Journal ArticleDOI
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
Caicun Zhou,Lin Wu,Yun Fan,Zhehai Wang,Lianke Liu,Gongyan Chen,Li Zhang,Dingzhi Huang,Shundong Cang,Zhixiong Yang,Jianying Zhou,Chengzhi Zhou,Baolan Li,Juan Li,Min Fan,Jiuwei Cui,Yuping Li,H. Zhao,Jian Fang,Jianxin Xue,Chengping Hu,Ping Sun,Yingying Du,Hui Zhou,Shuyan Wang,Wen Zhang +25 more
TL;DR: In this article, the authors conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with GP.
Journal ArticleDOI
Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer
TL;DR: The results suggest that the blood‐based EGFR mutations test has the ability to provide a reliable guidance for clinical decision making for the treatment of the advanced NSCLC patients.
Journal ArticleDOI
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang,J. Zhou,Jianying Zhou,Jifeng Feng,Wu Zhuang,Jianhua Chen,Jun Zhao,Wei Zhong,Yanqiu Zhao,Yiping Zhang,Yong Song,Yi Hu,Zhuang Yu,Y. Gong,Yuan Chen,Feng Ye,Shucai Zhang,Lejie Cao,Yun Fan,Gang Wu,Yubiao Guo,Chengzhi Zhou,K. Ma,Jian Fang,Weineng Feng,Yunpeng Liu,Zhendong Zheng,Gaofeng Li,Ning Wu,Wei Song,Xiaoqing Liu,Shijun Zhao,Lieming Ding,Li Mao,Giovanni Selvaggi,Xiaobin Yuan,Yuanqing Fu,Tao Wang,Shanshan Xiao,Li Zhang +39 more
TL;DR: Ensigninib has activity and is well tolerated in patients with crizotinib-refractory, ALK-positive NSCLC, including those with brain metastases, and the role of ensartinib in patients in whom other second-generation ALK inhibitors have been unsuccessful warrants further studies.
Journal ArticleDOI
Ferrous metal-organic frameworks with strong electron-donating properties for persulfate activation to effectively degrade aqueous sulfamethoxazole
TL;DR: This work provides a new prospect into the synthesis of high-performance MOFs with strong electron-donating properties as efficient persulfate activators, which may encourage the employ of MOFs in the wastewater treatment process.